S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

from OncLive® On Air · host OncLive® On Air

Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and the benefits omidubicel provides beyond improved neutrophil engraftment.

Episode metadata supplied by the publisher feed · Published May 15, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

0:00 9:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 9 minutes long.

When was this OncLive® On Air episode published?

This episode was published on May 15, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!